Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia

Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia

Ibrutinib is a covalently binding inhibitor of the B-cell receptor signaling-mediator Bruton’s tyrosine kinase (BTK) with great efficacy in chronic lymphocytic leukemia (CLL). Common side effects like atrial fibrillation (AF), bleeding and infections might be caused by ibrutinib’s inhibition of othe...

Full description

Bibliographic Details
Main Authors: Tom A. Mulder, Lucía Peña-Pérez, Anna Berglöf, Stephan Meinke, H. Yesid Estupiñán, Kia Heimersson, Rula Zain, Robert Månsson, C. I. Edvard Smith, Marzia Palma
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000564

Internet

http://journals.lww.com/10.1097/HS9.0000000000000564

Similar Items